Current management of SARS‐CoV‐2 infection in solid organ transplant recipients: Experience derived from an ESGICH–ESOT survey

Abstract

AbstractObjectiveSolid organ transplant (SOT) recipients have a poorer SARS‐CoV‐2 vaccine response and higher risk for COVID‐19‐associated complications. However, there is no consensus on the current management of COVID‐19 and data on persistent COVID‐19 rates in SOT recipients are lacking.MethodsAn electronic survey concerning the management of COVID‐19 in SOT recipients was distributed among all members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) and of the European Society for Organ Transplantation (ESOT). Four major sections were covered: prevention, early COVID‐19, late COVID‐19, and persistent COVID‐19. We developed a structured questionnaire including eight multiple‐choice questions with branching logic in case of positive answers and three open‐ended questions related to clinical practice. Questions were asked separately for lung and non‐lung transplantation.ResultsThirty‐two physicians from 24 different centers participated. Most answers (n = 30) were provided by European physicians. Thirty of 32 (93.75%) physicians managed non‐lung transplant recipients and 12 of 32 (33.3%) lung transplant recipients. There was a huge variability in practice regarding the treatment of COVID‐19, and particularly noticeable when considering lung and non‐lung transplant recipients. Main discordances included the use of nirmatrelvir alone or in combination therapy for early COVID‐19, the use of immunomodulatory drugs other than steroids for late COVID‐19, and the need for treating asymptomatic viral shedding in persistent COVID‐19. There was more similarity in terms of prophylaxis recommendations.ConclusionDespite a low number of respondents, this survey shows that there are many differences on how experts manage SARS‐CoV‐2 infections in SOT recipients. image